scholarly journals P345. The Great Continental Divide: use of anti-TNF therapy in paediatric inflammatory bowel disease is significantly different in North America compared with other parts of the world.

2016 ◽  
Vol 10 (suppl 1) ◽  
pp. S269-S269
Keyword(s):  
Inflammatory Bowel Disease ◽  
North America ◽  
Bowel Disease ◽  
Continental Divide ◽  
The World ◽  
Inflammatory Bowel

scholarly journals Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey

2020 ◽  
Author(s):  
Charles N Bernstein ◽  
Siew C Ng ◽  
Rupa Banerjee ◽  
Flavio Steinwurz ◽  
Bo Shen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Task Force ◽  
Health Care Systems ◽  
Underlying Disease ◽  
Virus Spread ◽  
The World ◽  
Management Guidance ◽  
Care Systems ◽  
Inflammatory Bowel

Abstract Background and Aims Persons with inflammatory bowel disease (IBD) may be particularly vulnerable to COVID-19 either because of their underlying disease or its management. Guidance has been presented on the management of persons with IBD in the time of this pandemic by different groups. We aimed to determine how gastroenterologists around the world were approaching the management of IBD. Methods Members of the World Gastroenterology Organization (WGO) IBD Task Force contacted colleagues in countries largely beyond North America and Europe, inviting them to review the WGO website for IBD and COVID-19 introduction, with links to guideline documents, and then to respond to 9 ancillary open-ended management questions. Results Fifty-two gastroenterologists from 33 countries across 6 continents completed the survey (April 14 to May 16, 2020). They were all adhering for the most part to published guidelines on IBD management in the COVID-19 era. Some differences and reductions in services related to access, and some related to approach within their communities in terms of limiting virus spread. In particular, most gastroenterologists reduced in-person clinics (43 of 52), limited steroid use (47 of 51), limited elective endoscopy (45 of 52), and limited elective surgeries (48 of 51). If a patient was diagnosed with COVID-19, immunomodulatory therapy was mostly held. Conclusions In most countries, the COVID-19 pandemic significantly altered the approach to persons with IBD. The few exceptions were mostly based on low burden of COVID-19 in individual communities. Regardless of resources or health care systems, gastroenterologists around the world took a similar approach to the management of IBD.

Dysbiosis in Microbiome Leading to Colitis-Associated Cancer

2021 ◽  
pp. 142-169
Author(s):  
Priyamvada Priyamvada
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Risk Factor ◽  
Bowel Disease ◽  
Gut Microbiome ◽  
The Body ◽  
Physiological Processes ◽  
Microbiome Diversity ◽  
The World ◽  
Inflammatory Bowel

Colitis-associated cancers are a metastatic form of inflammatory bowel disease considered a vital health associated risk factor causing the death of approximately five lacs people every year throughout the world. There are trillions of bacteria that are associated with our gut as a part of our healthy microbiome. The microbiota plays a plethora of important role in determining the normal physiological processes of the cells and, subsequently, the body. The imbalance in microbiome diversity (dysbiosis) due to abnormal dietary habitats, hectic lifestyle, and other factors thus alters the normal physiological processes of the body, thereby causing several chronic diseases. Therefore, it is essential to maintain the homeostasis between the host and their gut microbiome. So, based on the facts mentioned above, this chapter is entirely devoted to providing an overview of colitis-associated cancer and their relation with the dysbiosis of a healthy microbiome. Moreover, the mechanism involved in the development of colorectal cancer and its preventive insights has also been addressed.

scholarly journals Aspects of the Pathogenesis and Management of Inflammatory Bowel Diseases

2021 ◽  
Vol 3 (3) ◽  
pp. 96-99
Author(s):  
Andrew S. Day
Keyword(s):  
Inflammatory Bowel Disease ◽  
Inflammatory Bowel Diseases ◽  
Bowel Disease ◽  
The World ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Over the last two decades, inflammatory bowel disease (IBD) has been diagnosed more often in many countries around the world, including in parts of the world where IBD was previously uncommon [...]

scholarly journals The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis

2022 ◽  
Author(s):  
Gilaad G Kaplan ◽  
Fox E Underwood ◽  
Stephanie Coward ◽  
Manasi Agrawal ◽  
Ryan C Ungaro ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Latin America ◽  
North America ◽  
Trend Analysis ◽  
Bowel Disease ◽  
Temporal Trend ◽  
Temporal Trends ◽  
International Registry ◽  
Inflammatory Bowel

Abstract Background Cases of coronavirus disease 2019 (COVID-19) have emerged in discrete waves. We explored temporal trends in the reporting of COVID-19 in inflammatory bowel disease (IBD) patients. Methods The Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is an international registry of IBD patients diagnosed with COVID-19. The average percent changes (APCs) were calculated in weekly reported cases of COVID-19 during the periods of March 22 to September 12, September 13 to December 12, 2020, and December 13 to July 31, 2021. Results Across 73 countries, 6404 cases of COVID-19 were reported in IBD patients. COVID-19 reporting decreased globally by 4.2% per week (95% CI, −5.3% to −3.0%) from March 22 to September 12, 2020, then climbed by 10.2% per week (95% CI, 8.1%-12.3%) from September 13 to December 12, 2020, and then declined by 6.3% per week (95% CI, −7.8% to −4.7%). In the fall of 2020, weekly reporting climbed in North America (APC, 11.3%; 95% CI, 8.8-13.8) and Europe (APC, 17.7%; 95% CI, 12.1%-23.5%), whereas reporting was stable in Asia (APC, −8.1%; 95% CI, −15.6-0.1). From December 13, 2020, to July 31, 2021, reporting of COVID-19 in those with IBD declined in North America (APC, −8.5%; 95% CI, −10.2 to −6.7) and Europe (APC, −5.4%; 95% CI, −7.2 to −3.6) and was stable in Latin America (APC, −1.5%; 95% CI, −3.5% to 0.6%). Conclusions Temporal trends in reporting of COVID-19 in those with IBD are consistent with the epidemiological patterns COVID-19 globally.

Diagnostic and Treatment Methods for Ulcerative Colitis and Colitis-Associated Cancer

2021 ◽  
pp. 67-95
Author(s):  
Syed Nasar Rahaman ◽  
Prathiba Sivaprakasam ◽  
Ashok Kumar Pandurangan ◽  
Suresh Kumar Anandasadagopan
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Health Problem ◽  
Bowel Disease ◽  
The Other ◽  
Diallyl Trisulfide ◽  
Beneficial Effects ◽  
Natural Agents ◽  
The World ◽  
Inflammatory Bowel

Ulcerative colitis (UC) is a serious health problem around the world. Inflammatory bowel disease (IBD) is comprised of both Crohn's disease (CD) and UC. IBD is a clinical condition referred as inflammation in the colon. So far there is no proper medication available to treat IBD. On the other hand, untreated UC can be developed as colitis associated cancer. Natural agents are diverse molecules possess many beneficial effects. Many researchers have proven that natural agents can be better option to treat UC. Natural agents such as chrysin, chelidonic acid, euphol, fish oil, diallyl trisulfide, embelin, isatin, and rutin were already reported to have anti-colitic activity. In this chapter, the authors documented the natural agents that were used as treatment for UC.

Underutilization of Bowel Ultrasound in North America in Children with Inflammatory Bowel Disease

2019 ◽  
Vol 38 (5) ◽  
pp. 390-397
Author(s):  
Heidi E. Gamboa ◽  
Zarela Molle-Rios ◽  
Sudha A. Anupindi
Keyword(s):  
Inflammatory Bowel Disease ◽  
North America ◽  
Bowel Disease ◽  
Bulletin Board ◽  
Observer Variability ◽  
The North ◽  
Widespread Adoption ◽  
Inter Observer Variability ◽  
Inflammatory Bowel ◽  
Bowel Ultrasound

Background: Inflammatory bowel disease (IBD) is a chronic relapsing disease that requires evaluation using multiple objective tools. In Europe, bowel ultrasound (US) is a widely accepted modality used for the management of patients with IBD; however, its use in North America has only recently emerged as a potential technique. Objectives: Our goal was to identify current practice patterns of pediatric gastroenterologists and radiologists using bowel US in patients with IBD and highlight perceived limitations to the widespread adoption of this modality in North America. Methods: A 14-question survey was e-mailed to the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition internet bulletin board composed of 3,058 subscribers from 51 countries; the Society of Pediatric Radiology listserv composed of 1,917 subscribers worldwide; and the Society of Chairs of Radiology at Children’s Hospitals listserv. Descriptive summary statistics was used. Results: In North America, about one-quarter of gastroenterology and radiology participants reported using bowel US for IBD; over 3-fourths expressed an interest in using US more often. Bowel US was performed more frequently for Crohn’s disease. Both groups agreed the main limitation to using bowel US was concern for inter-observer variability and operator-dependent factors; radiologists reported that other modalities are more effective to assess IBD, whereas gastroenterologists reported unfamiliarity with bowel US indications and techniques. Conclusions: Our data show there is significant interest among both radiologists and gastroenterologists in using bowel US. However, lack of education, insufficient training, and perceived high inter-observer variability among US technologists are limitations preventing the widespread adoption of US for IBD in North America.

Sign in / Sign up

Export Citation Format

Share Document